BioCentury | Oct 13, 2017
Clinical News

End of the road for Merck's anacetrapib

...and Co. (NYSE:LLY), and Pfizer Inc. (NYSE:PFE) previously discontinued development of CETP inhibitors dalcetrapib , evacetrapib...
BioCentury | Oct 12, 2017
Clinical News

End of the road for Merck's anacetrapib

...Lilly and Co. (NYSE:LLY), and Pfizer Inc. (NYSE:PFE) previously discontinued development of CETP inhibitors dalcetrapib, evacetrapib...
...and torcetrapib, respectively, based on results of Phase III trials (see BioCentury, Jul. 7) . Allison Johnson anacetrapib dalcetrapib evacetrapib MK-0859 torcetrapib Eli...
BioCentury | Jul 7, 2017
Product Development

One small CETP for Merck

...events. Then in 2015, Eli Lilly and Co. terminated the Phase III ACCELERATE trial of evacetrapib...
...study, anacetrapib treatment led to a 45% LDL reduction and a 150% increase in HDL. Evacetrapib...
...the efficacy signal. REVEAL had a median follow-up of four years, whereas the follow-up for evacetrapib...
BioCentury | Jun 27, 2017
Clinical News

Merck's CETP inhibitor meets in CV outcomes study

...11, 2006) . In 2015, Eli Lilly and Co. (NYSE:LLY) discontinued development of evacetrapib ( LY2484595...
...the product from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) (see BioCentury, Sept. 21, 2015) . Chris Lieu AMG 899 anacetrapib dalcetrapib evacetrapib TA-8995 Amgen...
BioCentury | Jan 14, 2016
Distillery Therapeutics

Therapeutics: Cholesteryl ester transfer protein (CETP)

...BMS-795311 in preclinical testing for cardiovascular indications. Eli Lilly and Co. has the CETP inhibitor evacetrapib...
BioCentury | Jan 4, 2016
Finance

Big band swing

...trials to treat diabetic foot ulcers Eli Lilly and Co. (NYSE:LLY) Discontinues development of evacetrapib (LY2484595...
BioCentury | Nov 14, 2015
Clinical News

Merck continues anacetrapib CVOT

...Last month, Eli Lilly and Co. (NYSE:LLY) discontinued development of CETP inhibitor evacetrapib ( LY2484595...
BioCentury | Oct 19, 2015
Clinical News

Evacetrapib: Development discontinued

...Eli Lilly will discontinue development of evacetrapib to treat high-risk atherosclerotic cardiovascular disease after an IDMC...
...endpoint; the study is not being stopped for safety findings. Lilly said all studies of evacetrapib...
...<=4 years in 12,095 patients. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Evacetrapib ( LY2484595...
BioCentury | Oct 13, 2015
Top Story

Lilly discontinues Phase III CETP inhibitor

...it will discontinue development of cholesteryl ester transfer protein ( CETP ) inhibitor evacetrapib ( LY2484595...
...at an upcoming scientific meeting. Lilly spokesperson Scott MacGregor told BioCentury that all studies of evacetrapib...
...smaller studies." ACCENTUATE measured LDL-C reduction in patients with high cholesterol. In 2011, Lilly said evacetrapib...
BioCentury | Sep 28, 2015
Clinical News

Evacetrapib: Phase III ongoing

...recommended continuation of the double-blind, placebo-controlled, international Phase III ACCELERATE trial evaluating 130 mg oral evacetrapib...
...from an interim futility analysis. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Evacetrapib ( LY2484595...
Items per page:
1 - 10 of 20